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Abstract
A pancreatoduodenectomy specimen is complex, and there is much debate on how it is best approached by the pathologist. In this
review, we provide an overview of topics relevant for current clinical practice in terms of gross dissection, and macro- and
microscopic assessment of the pancreatoduodenectomy specimen with a suspicion of suspected pancreatic cancer. Tumor origin,
tumor size, degree of differentiation, lymph node status, and resection margin status are universally accepted as prognostic for
survival. However, different guidelines diverge on important issues, such as the diagnostic criteria for evaluating the complete-
ness of resection. The macroscopic assessment of the site of origin in periampullary tumors and cystic lesions is influenced by the
grossing method. Bi-sectioning of the head of the pancreas may offer an advantage in this respect, as this method allows for
optimal visualization of the periampullary area. However, a head-to-head comparison of the assessment of clinically relevant
parameters, using axial slicing versus bi-sectioning, is not available yet and the gold standard to compare both techniques
prospectively might be subject of debate. Further studies are required to validate the various dissection protocols used for
pancreatoduodenectomy specimens and their specific value in the assessment of pathological parameters relevant for prognosis.
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Introduction
Pancreatoduodenectomy (PD) specimens is are among the
most complex resection specimens encountered by patholo-
gists. PD is performed most often for oncological reasons,
such as (pre)cancerous lesions of the pancreas, ampulla, duo-
denum, and distal bile duct. In this review, we provide an
overview of topics relevant for current clinical practice, in
terms of both macro- and microscopic assessment of PD spec-
imens with a suspicion of pancreatic cancer.
Careful evaluation is imperative to properly assess tumor
origin for staging and to select postoperative treatment strate-
gies. We describe how different grossing techniques may in-
fluence the assessment, and we discuss (potentially) relevant
pathological parameters in terms of postoperative treatment
and prognosis in relation to the current literature, i.e., tumor
origin, completeness of resection, and tumor spread.
The relevance of the different histopathological character-
istics has been studied extensively. Based on a retrospective
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analysis of 555 patients who underwent pancreatic resection
for pancreatic ductal adenocarcinoma (PDAC), Brennan et al.
developed a nomogram in which they present clinical and
histopathological variables relevant for survival [1].
Resection margin status, degree of differentiation, number of
tumor-negative and tumor-positive lymph nodes, T-stage, and
tumor size were identified as relevant histopathological pa-
rameters on Cox multivariable analysis.
Grossing techniques
To improve the quality of pathological assessment, different
proposals for standardization of gross dissection protocols and
multicolor inking have been published over the past decades.
In our experience, two of these protocols are most commonly
used. The first is the axial sectioning method: each specimen
is serially sliced perpendicular to the long axis of the duode-
num over its entire craniocaudal length [2].
The second method involves bi-valving of the specimen
along the pancreatic duct and the common bile duct (CBD).
After bi-sectioning, the two halves can be serially sliced in
three different planes: either by axial slicing, multi-valving
(serial slicing along each half of the pancreas), or bread
loafing (parallel to the neck of the pancreas) [3].
To the best of our knowledge, there are no prospec-
tive studies comparing the different protocols head-to-
head regarding establishing tumor origin, completeness
of resection, and evaluation of tumor spread. A direct
comparison of the different grossing techniques regard-
ing diagnostic assessment of relevant pathological pa-
rameters is therefore not possible in this review. There
is no gold standard, although The Royal College of
Pathologists (RCP) favors the axial slicing method [4].
The axial slicing method, propagated by Verbeke, has sev-
eral major advantages [2]. For every surgical specimen the
same protocol is used, making it easy to perform. The circum-
ferential margins are readily assessable (Fig.1). However,
some aspects can be more difficult to evaluate using this pro-
tocol. The optimal plane of the section for capturing the am-
pullary region cannot be ascertained beforehand; as a result,
the ampullary region frequently happens to fall between sec-
tions, hindering accurate assessment of tumor origin [3].
Moreover, the value of axial slicing in case of ampullary and
cystic tumors has not been explored. This is relevant, as the
origin of periampullary tumors and cystic tumors is often in-
conclusive on preoperative imaging. Furthermore, in case of
an intraductal papillary mucinous neoplasm (IPMN), axial
slicing does not allow to distinguish between lesions originat-
ing from the main pancreatic duct or side branches.
Determining the precise tumor origin may be especially rele-
vant for ampullary tumors: in a large cohort study, four sub-
types of ampullary carcinomas were identified based on their
origin, with differences in prognosis in this otherwise hetero-
geneous group of cancer [5]. This subclassification has recent-
ly been adopted by the College of American Pathologists for
synoptic reporting [6].. The articles reporting on this subclas-
sification use the bi-sectioningmethod for grossing. It remains
to be seen whether axial slicing is suited for this subclassifi-
cation of ampullary cancers [5].
Bi-sectioning of the head of the pancreas, as described by
Adsay, is technically more difficult to perform [3]. Briefly,
small probes are inserted into the pancreatic duct and CBD.
The head is sliced in the plane defined by the two probes,
exposing both ducts longitudinally. The pancreatic duct is
either approached from the ampullary orifice or from the pan-
creatic neckmargin (Fig. 2). Probing the entire pancreatic duct
is not always possible due to occlusion by tumor compression,
tumor growth or reactive changes. The bi-sectioning method
can be modified if needed; in case of a suspicion of distal
cholangiocarcinoma, the CBD is most important to visualize,
whereas the pancreatic duct takes preference in cystic lesions.
However, it does have important advantages compared to ax-
ial slicing. The periampullary region is always visualized and
the primary origin of periampullary tumors (pancreas, duode-
num, CBD, and ampulla of Vater) can be more reliably appre-
ciated. For ampullary tumors, the tumor origin can be more
accurately assessed, which facilitates subtyping of this tumor
[5]. Additionally, bi-sectioning allows much more accurate
documentation of cystic tumors and their relationship to the
ducts; after successful bi-sectioning, the main pancreatic duct
can be completely evaluated, inked if appropriate and a dis-
tinction can be made between the CBD, main pancreatic duct,
and side branches, facilitating diagnosis of main and/or side
branch IPMN.
Regarding the search for lymph nodes, the RCP propagates
a minimum yield of 12 lymph nodes, as this number was
optimal for accurate staging of node-negative patients [4]. In
order to maximize the number of harvested lymph nodes,
Verbeke and Adsay describe different methods. Verbeke uses
extensive perpendicular sampling of the lamellated pancreas
with its surrounding soft tissue, whereas Adsay uses the so-
called Borange peeling method^ to procure a maximum num-
ber of lymph nodes [7]. The orange peelingmethod consists of
shaving off the all peripancreatic soft tissue after multicolor
inking. The shaved off tissue derived from the superior mes-
enteric vessel margin is bread-loafed and submitted entirely.
Potential tumor-involved margins can also be submitted in
their entirety, enabling margin assessment. Manual lymph
node dissection is performed on the remaining tissue.
Manual dissection may reduce double counting of lymph
nodes, as the retrieved lymph nodes can be submitted in one
cassette. The left-over fatty tissue is then submitted for the
detection of microscopic lymph nodes. The authors conclude
that the orange peeling method considerably increases the
lymph node yield; however, it is unclear against which
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Bconventional^ method of searching for lymph nodes it was
compared. The increased lymph node yield might be ex-
plained by the fact that more fatty tissue is included for mi-
croscopic examination. Double counting of lymph nodes re-
mains an issue of concern in both methods.
In many institutions, a small sample of fresh tumor tissue is
harvested for research purposes. To do so, multicolor inking
and slicing should be performed on the freshly received spec-
imen. The difficulty in distinguishing tumor tissue from
chronic and fibrosing inflammation in the surrounding pan-
creatic tissue makes correct sampling challenging. A good
view of the tumor is imperative. There is no literature on
which method is optimal for fresh tumor sampling.
Tumor characteristics
Site of origin, tumor size and tumor type are important param-
eters that should be considered when evaluating a PD
specimen. Each parameter has its own challenges, and we
review the parameters that should be considered when evalu-
ating a PD specimen with a suspicion of PDAC.
Site of origin
When PD is performed for a malignant tumor, one of the first
steps is to ascertain the site of origin of the primary tumor,
which cannot always be easily assessed in this anatomically
complex area. The papilla of Vater is the protrusion into the
duodenal lumen caused by the ampulla of Vater, which is
formed by dilated junction of the distal pancreatic duct and
the distal CBD. The ampulla of Vater is surrounded by the
sphincter of Oddi. In the periampullary region, three distinct
types of epithelial lining are joining: the duodenal surface of
the ampulla, lined by intestinal epithelium; the ampulla of
Vater, lined by foveolar-like mucosa with scattered goblet
cells; and the distal ends of the CBD and pancreatic duct, lined
by pancreatobiliary-type epithelium. Pancreatic duct glands
and the peribiliary glands harbor pancreatic stem cells and
biliary tree progenitor cells, and these may contribute to tumor
heterogeneity [8]. Due to the complex anatomy, the
periampullary area gives rise to a heterogeneous group of
tumors, each with their own histologic features and biological
behavior [9].
The minor duodenal papilla, which drains the accessory
duct of Santorini, is situated 2 cm proximal to the major pa-
pilla. It is usually identifiable by close inspection, unless it is
obliterated by tumor or severe inflammation. The minor duo-
denal ampulla is lined with pancreaticobiliary-type epitheli-
um, identical to the epithelium lining the distal CBD and pan-
creatic duct and surrounded by a smooth muscle layer. The
muscle layer is known as the sphincter of Helly, although there
is some debate whether it should be considered a proper
sphincter. All tumors that can occur in the pancreatic duct
and the major papilla have also been reported as occurring in
Fig. 1 a Example of an axially sliced specimen. The tumor of the head of the pancreas involves the common bile duct, but does not appear to originate
from it. b Close-up of the tumor. The margin of the neck of the pancreas has already been shaved
Fig. 2 Example of a bi-valved specimen. The periampullary tumor does
not involve the pancreatic or common bile duct. The common bile duct is
distended due to compression by the tumor at the ampullary level
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the minor papilla and the duct of Santorini, and awareness of
the possibility of a tumor in the minor papilla might contribute
to better tumor subtyping [10].
Adenocarcinomas in the periampullary region can arise
from the duodenum, ampulla of Vater, distal CBD, or pancre-
atic duct. Importantly, different TNM staging and adjuvant
therapies apply to each of these distinct tumors [9]. In addi-
tion, the primary tumor site may be an in- or exclusion crite-
rion for clinical trials.
In practice, the primary site of origin of the tumor is mainly
determined macroscopically, based on the location of the tu-
mor bulk. In particular in voluminous tumors, the site of origin
can be difficult to assess. In general, when the tumor origin
cannot be determined, most pathologists choose a default
Bmost likely^ diagnosis of PDAC, as it is most frequently
encountered and has a defined treatment strategy. It is gener-
ally accepted that patients with PDAC have a worse prognosis
than patients with cholangiocarcinoma or ampullary carcino-
ma. In fact, survival of patients with PDAC may even be
overest imated due to misclassif ied PDACs [11].
Interestingly, two retrospective analyses of 510 and 198 PDs
found that the histopathological subtype of periampullary ad-
enocarcinomas may be a better predictor of patient survival
than the site of origin [12, 13]. In these studies, patients with a
pancreaticobiliary subtype of ampullary or cholangiocarcino-
ma had a survival like that of patients with PDAC, whereas the
intestinal subtype was associated with longer survival.
Unfortunately, neither study described the method of gross
dissection.
Tumor definitions
PDAC is defined by theWorld Health Organization (WHO) as
an infiltrating epithelial neoplasm with glandular (ductal) dif-
ferentiation, usually demonstrating mucin production without
a predominant component of any other histological subtype.
An abundant desmoplastic stromal response is a typical fea-
ture [14]. Themorphologic features of extrahepatic cholangio-
carcinoma are very similar to those of PDAC.
Extrahepatic (distal) cholangiocarcinoma is defined by the
WHO as a malignant epithelial tumor with glandular differen-
tiation arising in the extrahepatic biliary system [14]. This
includes tumors arising in the intrapancreatic part of the
CBD. It is often difficult to distinguish a tumor arising in the
pancreas and secondarily involving the CBD from a tumor
arising in the CBD and secondarily growing into the pancreas,
in part because there are few distinct morphologic features
pointing to either origin. When a distal cholangiocarcinoma
or PDAC involves the entire ampulla, the pathologist faces a
similar dilemma. Microscopic features that may point to a bile
duct origin are dysplasia within the CBD, circumferential in-
volvement of the bile duct by invasive carcinoma,
intraglandular neutrophil-rich debris, and a small tubular
growth pattern [15]. The difficulty in determining the primary
origin of periampullary tumors together with the lack of a
clear guidance by the WHO is a source of confusion lead-
ing to a lack of conformity in diagnosis. The incidence of
distal cholangiocarcinoma is likely underestimated, as in
different series the estimated incidence shows a wide
range in [11]. Reevaluation of patients registered with
PDAC also shows frequent misclassification of distal
cholangiocarcinoma [16, 17].
Ampullary carcinoma is defined by the WHO as a gland-
forming malignant epithelial neoplasm, originating in the am-
pulla of Vater. Only carcinomas either centered on the ampul-
la, or circumferentially surrounding it, or completely replacing
the ampulla are considered ampullary carcinomas [14]. In
large tumors, for which this criterion can no longer be
assessed, the presence of precursor lesions at the level of the
ampulla may be of help. There is no specific subclassification
for tumors arising from the different compartments of the am-
pulla of Vater. Owing to the lack of a clear description of what
encompasses the Bampulla of Vater,^ the significance of tu-
mors arising from different sites within this complex region
has not yet been elucidated. To reduce ambiguity of the entity,
ampullary carcinomas are sometimes subclassified based on
location into four categories, namely intra-ampullary, ampul-
lary-ductal, periampullary duodenal, and ampullary carcino-
ma not otherwise specified. The categories were proposed
after a retrospective analysis of 249 ampullary carcinomas,
each category with a difference in survival [5]. However, this
subclassification needs further validation.
Tumor size
Tumor size (defined as the largest dimension of the tumor as
assessed at pathology) is a well-established predictor of sur-
vival in PDAC and determines T-category for tumors limited
to the pancreas. Generally, patients with a tumor size < 3 cm
have a better prognosis, but this is mostly only significant in
univariate analyses [18–20]. Multivariate analysis with cor-
rection for spread into peripancreatic soft tissue and surround-
ing structures is occasionally applied [21]. Saka et al. de-
scribed staging based on tumor size—rather than T-catego-
ry—as a viable method [22]. Multivariate analysis was used,
with adjustment for age, sex, International Union Against
Cancer (UICC) N-stage, margin status, and lymphovascular/
perineural invasion. T-category was not considered, but more
than 95% of cases had peripancreatic soft tissue involvement.
Cutoff values of ≤ 2, > 2–4, and > 4 cm were found highly
significant in terms of prognosis, both in their own cohort of
223 PD specimens and in the SEER database. In the eighth
edition of the TNM, which came into effect in January 2018,
peripancreatic soft tissue involvement is no longer a factor in
the determination of T-category. T1-T3 is dependent only on
tumor size, whilst T4 requires tumor involvement of the
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coeliac axis, superior mesenteric artery, and/or common he-
patic artery [23].
Intraductal papillary mucinous neoplasm
IPMN is a precursor lesion to PDAC that is regularly seen in
clinical practice and has received much attention lately.
Histologically, gastric-type, intestinal-type, oncocytic type,
and pancreatobiliary-type IPMNs are discriminated. These
different histological subtypes have been associated with dif-
ferent clinicopathological features, such as risk of high-grade
dysplasia and malignant transformation. However, there is a
debate about the clinical relevance of these subtypes since
multiple subtypes are often present within the same IPMN
and histological subtyping is difficult to reproduce in a sub-
stantial number of cases [24].
IPMNs are also subclassified as main duct-type or side
branch-type, based on the location of involvement of the pan-
creatic duct, which is assessed by imaging. In addition, some
IPMNs involve both the main pancreatic duct and the side
branches and are called mixed-type IPMNs. IPMNs confined
to a side branch rarely evolve into malignancy and have a
better prognosis than main duct and mixed-type IPMNs
[25–28]. There are no studies comparing the correlation be-
tween imaging findings and pathological findings in the dis-
t inc t ion be tween main and s ide b ranch IPMN.
Macroscopically, bi-valvingwill visualize the entire main pan-
creatic duct, potentially facilitating the determination of IPMN
location.
PDACs arising in an IPMN have a better prognosis than
PDACs not associated with IPMN.When assessing the size of
a tumor arising in an IPMN, only the invasive portion should
be taken into account to determine the T-category [29].
However, it is often difficult to discriminate the invasive from
the non-invasive part macroscopically. In addition,
multifocality can make it difficult to measure the diameter of
the invasive component.
Perineural and vasoinvasive growth
While both the presence of perineural and vasoinvasive
growth have long been established as poor prognostic factors
for many malignancies including PDAC, little is published
about the value of these parameters in PDAC. Although some
studies have shown that perineural and vasoinvasive growth
are predictive of a worse outcome in univariate or multivariate
analysis [30–32], other studies did not confirm this [20, 33,
34]. The incidence of perineural invasion varies between 31
and 92% across studies. The reported incidence of vascular
invasion is lower, varying between 9 and 55% [20, 30–32]. As
vascular elastic stains are not commonly used in the assess-
ment of PDAC, vascular invasion can be easily missed.
Assessment of resection margins
Multiple names are used to designate the different mar-
gins of the PD specimen. (See Table 1). Here, we use the
names used by the RCP. The transection margins are the
pancreatic neck margin, the CBD, the proximal stomach
or duodenum and the distal duodenum or jejunum margin.
The superior mesenteric vessel margin (including the su-
perior mesenteric vein and artery margin) is considered a
dissection margin. The superior mesenteric vessel margin
is most frequently involved by tumor cells, most likely
due to the lack of peripancreatic soft tissue in this area
[35, 36]. The anterior surface is covered by peritoneum
and considered a Bfree surface^ rather than a dissection
margin. Even so, involvement of this surface likely in-
creases the risk of recurrence [37]. According to the
RCP, the anterior surface should be considered in margin
assessment. In contrast, the College of American
Pathologists does not consider the free anterior surface
for tumor involvement [38].
The same discussion applies to the posterior surface. As
argued by some, the posterior-right aspect of the pancreas—
where the pancreatic head transitions into the duodenum—is
covered by smooth connective tissue, rendering it a free mar-
gin [3]. However, many consider the posterior margin a dis-
section margin because the pancreas is dissected from the
surrounding retroperitoneal soft tissue [39]. In colon cancer,
tumor extension into the overlying peritoneum is relevant for
the T-category and is associated with decreased survival [40].
Whether this is also true for pancreatic cancer has not been
investigated to our knowledge.
R1 resection
The definition of a microscopic incomplete (R1) resection
differs across countries and centers. The UICC defines R1 as
microscopic residual disease, without further specifying the
type of margin (transection or dissection) or the mode of prop-
agation (direct or indirect). In Europe and Japan, the presence
of tumor cells < 1 mm from the resection margin is generally
considered an incomplete resection, whereas in the USA, a
resection is considered incomplete only when tumor cells are
present in the margin. The rule of 1 mm clearance is adopted
from the circumferential margin assessment in rectal carcino-
ma. In pancreas resection specimens, studies have shown that
an R0 resection only carries any prognostic value when it is
defined as ≥ 1 mm margin clearance [41, 42]. Two studies
found that a margin clearance of ≥ 1.5 or ≥ 2mm, respectively,
is an even better predictor of survival than a margin clearance
of ≥ 1 mm [43, 44]. However, after correction for tumor size
and other clinicopathological parameters, margin clearance
only remained an independent prognostic factor in the study
that used a margin clearance of ≥ 1.5 mm. Recently, a
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prospective study evaluated the relevance of resection margin
status for survival in 561 patients, of whom the majority had
received adjuvant treatment [36]. Of these patients 80% had
an R1 resection (< 1 mm clearance), of which 58% had direct
margin involvement (0 mmmargin clearance). In multivariate
analysis, R1-status was independently associated with surviv-
al; a tumor clearance of ≥ 1 mm best identified the subgroup
with favorable survival. The RCP pointed out that the ≥ 1 mm
margin clearance should only apply to true transection and
dissection margins, excluding the anterior free surface [4].
The definition which is used for microscopic incomplete
resection affects tumor sampling and the number of blocks to
be taken. When an incomplete resection is defined as direct
involvement of the margin, the peripancreatic tissue may be
sampled without special care for tissue orientation (e.g., or-
ange peeling) [3]. However, when defining R1 as < 1 mm
clearance, the relation between the inked margin and underly-
ing (fatty) tissue must be preserved, necessitating extensive
perpendicular sampling of margins that are threatened onmac-
roscopic assessment [37]
R1 percentage as a quality parameter
The percentage of R1 resections is often considered the most
important quality parameter of pathologic assessment of PD
specimens. In general, it is thought that meticulous assessment
should result in an R1-percentage of 70% or higher [37, 45].
Verbeke states that more R1 resections are detected in the axial
slicing method when compared to Btraditional^ (i.e., not axial
slicing) grossing methods, and that the axial slicing method is
therefore more sensitive for R1 resections [2]. For the nine
studies that are considered Btraditional,^ the grossing method
is often not clearly described. Moreover, the definition of an
R1 resection is not uniform: the included margins, as well as
the definition of a positive margin differ, being 0 mm in some
studies and < 1 mm in others. In our opinion, further studies
are needed to adequately compare the different grossing tech-
niques in terms of R1-percentage as a quality parameter.
Moreover, uniform and validated definitions for R1 need to
be specified.
Indirect tumor growth within the 1-mm margin
When tumor cells are present within 1 mm of the margin other
than by direct tumor spread (i.e., by lymphangio-invasion,
perineural invasion, or lymph node metastasis), it is unclear
if this should be considered an incomplete resection. The RCP
considers these cases to be R1-resections but offers no further
explanation. In contrast, for the UICC, these cases are consid-
ered to be R0-resections, except when vessel wall invasion is
present within 1 mm of the resection margin [46]. Similarly,
Verbeke argues that tumor cells present by perineural spread,
lymphangio-invasion or lymph node metastasis within 1 mm
of the margin qualifies the resection as complete, based on the
following arguments [47]. Firstly, the mode of propagation
and behavior of these tumor cells is different from that of
tumor cells that spread by direct invasion. Secondly, tumor
cells within a lymph node are encapsulated, hence the 0-mm
clearance approach seems to be appropriate. However, when
tumor cells breach the lymph node capsule and infiltrate the
surrounding soft tissue, the 1 mm rule becomes applicable.
Thirdly, lymphovascular and perineural tumor invasion are
reflective of regional spread, whilst R0 resection is commonly
understood to indicate successful local clearance of tumor.
Locoregional tumor recurrence because of lymph node metas-
tasis or spread along peripheral nerves cannot be prevented by
an R0 resection.
Lymph nodes
Tumor-positive lymph nodes
Metastasis to regional lymph nodes is independently associat-
ed with poor survival in PDAC [19, 20, 48, 49], although this
has not been found in all series [50, 51]. According to the
UICC, regional lymph nodes are grouped into anterior
pancreatoduodenal, posterior pancreatoduodenal, inferior (in-
cluding the lymph nodes around the superior mesenteric ves-
sels), CBD, coeliac, infrapyloric, and superior and proximal
mesentery lymph nodes [9]. Metastasis in non-regional LNs is
defined as distant metastasis (M1). The 7th edition of the
UICC staging system only considers the presence or absence
of regional nodal disease. In 2015, Basturk et al. analyzed in
227 PDACs the prognostic value of the other two substaging
Table 1 Different margin names
RCP name Also used
Superior mesenteric vessel
- Superior mesenteric vein
margin
- Superior mesenteric artery
margin
Medial margin
Uncinate margin
Retroperitoneal margin
Inferior-posterior
(retroperitoneal) margin
Mesopancreatic margin
Medial margin
Vascular margin
Posterior margin (part of) uncinated margin
(part of) retroperitoneal margin
Deep retroperitoneal posterior
surface
Proximal duodenal/gastric
Distal duodenal/jejunal
Pancreatic neck margin Pancreatic duct margin
Bile duct margin
Common bile duct margin
Anterior free surface Anterior margin
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protocols used for gastrointestinal malignancies, for which
lymph node assessment had been performed according to a
standard protocol. Whilst the N-category of upper gastrointes-
tinal malignancies (N0 no metastasis, N1 metastasis to 1–2
lymph nodes, N2 metastasis to > 2 lymph nodes) performed
best, they found that the N-category of the lower gastrointes-
tinal organs (N0 no metastasis, N1 metastasis to 1–3 lymph
nodes, N2 metastasis to > 3 lymph nodes) had significantly
more prognostic value than that used in the 7th edition of the
UICC [52]. In the eighth edition of the TNM, the N-category
matches that of the lower gastrointestinal organs [23]. The
Japan Pancreas Society distinguishes three N-categories and
gives a weighting factor according the location of the lymph
nodes [53]. In published series, microscopically tumor-
positive lymph nodes are found in up to 80% of surgical spec-
imens during routine examination [48, 54].
Tumor involvement of distant lymph nodes is associ-
ated with decreased survival in pancreatic cancer pa-
tients [55]. However, extended lymphadenectomy is dis-
couraged and seldom performed, as it has been shown
to be of limited value in long term survival, whilst
increasing morbidity [56].
Direct invasion of lymph nodes
Direct invasion of lymph nodes by continuous tumor growth
is present in about 5–10% of PD specimens. Two articles
report no difference in survival for patients with direct nodal
invasion versus those with lymph node metastasis, warranting
an interpretation of direct invasion as Bregular^ lymph node
positivity. Another article found that patients with isolated
lymph node involvement did have improved survival com-
pared to patients with metastasis to regional lymph nodes
[57]. The biological mechanisms responsible for eventual dif-
ferences between different modalities of tumor spread remain
unclear [57, 58].
Nodal micrometastases
A few studies have evaluated the implication of the
presence of isolated tumor cells or micrometastases in
lymph nodes [59–61] . The presence of nodal
micrometastases identified on immunohistochemistry ap-
pears to be an independent prognostic factor for patients
that were considered node-negative on routine histolog-
ical examination. These patients have similar survival
curves as N1 patients on routine examination. Patients
with tumor negative lymph nodes by immunohistochem-
istry have a markedly better survival compared to pa-
tients with micrometastases. These studies did however
not differentiate between nodal micrometastases and iso-
lated tumor cells.
Lymph node ratio
The lymph node ratio considers both the total number of
lymph nodes and the number of positive lymph nodes. It has
proven to be an important predictor for survival in pancreatic
cancer, although the predictive value of this parameter re-
mains proportional to the adequacy of lymph node yield
[48]. In addition, it has proven more predictive than the di-
chotomous presence or absence of nodal disease [62].
Extra-nodal lymph node spread
Extra-nodal tumor spread from tumor positive lymph nodes is
an adverse prognostic factor in many tumor types, including
rectal, thyroid, bladder and gastric cancer. Luchini et al. re-
cently published a review on the significance of extra-nodal
spread in PDAC [63]. It was associated with a poor prognosis
in terms of overall and disease-specific survival. For this rea-
son, they argue that its presence should be considered in on-
cologic staging and the choice of therapeutic approach. They
also concluded that extra-nodal tumor spread may be present
in more than 50% of N1 patients.
Peripancreatic soft tissue spread
Spread of a tumor outside of the pancreas into the surrounding
soft tissue or adjacent organs was a feature of T3 tumors
according to theTNM 7 classification. The assessment of tu-
mor spread into the peripancreatic soft tissue has a large mar-
gin of error, as the pancreas lacks a true capsule, meaning
there is no clear demarcation between pancreatic and
peripancreatic tissue. Peripancreatic soft tissue involvement
appears to be present in most cases. Saka et al. showed that,
when using the orange peeling method for the peripancreatic
soft tissue, tumor invasion is nearly always present (> 95%)
and therefore not a good predictor of survival [22]. Another
complicating factor when assessing tumor spread into
peripancreatic soft tissue is atrophy and fatty degeneration of
the exocrine pancreas. Islet cells may be of guidance in these
cases, as their presence indicates the previous level of the
exocrine pancreas. In the eighth edition of the TNM,
peripancreatic soft tissue spread is no longer relevant for the
T-category; only tumor size is considered in the definition of
T1-T3.
Neoadjuvant treatment
An increasing proportion of patients receives neoadjuvant
therapy, including chemotherapy and radiation therapy. The
influence of these treatments on the clinical relevance and
definition of R-status is still unknown [2, 64]. Reactive chang-
es such as fibrosis induced by neoadjuvant therapy, in post-
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treatment resection specimens might complicate the macro-
scopic identification of the tumor. Microscopic assessment
of these cases includes evaluation of the response to preoper-
ative treatment; however, there is no consensus on how tumor
regression should be graded [65]. In a large retrospective
study, Chatterjee compared 233 patients with no and minimal
residual disease to patients with moderate and poor response
[66]. They found that patients with no or minimal residual
disease have significantly improved survival. This advantage
remained after multivariate analysis including pathologic tu-
mor stage, margin status, and lymph node status. They con-
clude that histologic grading is an important prognostic factor.
Several grading schemes for the assessment of residual tumor
in post-treatment PD specimens have been proposed, includ-
ing the College of American Pathologists (CAP) and Evans
grading system [67, 68]. Recently, Lee et al. validated their
own 3-tiered histologic tumor regression grading (HTGR)
scheme (HTRG 0, no viable tumor; HTRG 1, < 5% viable
tumor cells; HTRG 2, ≥ 5% viable tumor cells). In multivari-
ate analysis, HTRG grade 0 or 1 was an independent prognos-
tic factor for better disease-free survival, but not for overall
survival [69]. In a recent retrospective cohort study, 398
PDAC patients who underwent neoadjuvant therapy and PD
were analyzed to validate the new size-based T-category def-
initions of the eight edition of the TNM [70]. The authors
showed that the new T stage system outperformed the old T
stage system in patients after neoadjuvant treatment.
Additionally, they found that a tumor size cutoff of 1.0 cm
worked better for T2 than the proposed tumor size cutoff of
2.0 cm in this group of patients. Interestingly, all nine patients
with a complete pathologic response showed no recurrence at
the end of follow-up.
Conclusion
We presented a comprehensive overview of the dilemmas the
pathologist may face in the assessment of a PD specimen.
Several different approached for gross dissection have been
proposed in the literature, each having its advantages and dis-
advantages about assessment of important clinicopathological
parameters. Compared with axial slicing, bi-valving seems
better suited for the assessment of tumor origin. The value in
terms of prognosis of some the clinicopathological parameters
(e.g., tumor size) has been evaluated by many studies.
However, most of these studies were retrospective and the
protocols and frequently used definitions lacked a standard-
ized histopathological approach, both at the macroscopic and
microscopic level. For several pathological parameters, e.g.,
completeness of resection, this has hampered clinical valida-
tion and further application. As a result, different organiza-
tions have published their own guidelines, which show diver-
gence on potentially important issues. Pathologists and
surgeons should be aware of these differences and of the un-
certainties in histopathological assessment of PDs.
Neoadjuvant therapy, which is increasingly administered, will
also influence the assessment of the specimen and the inter-
pretation of certain parameters in the resection specimen after
chemotherapy [65]. Further prospective studies are needed to
validate the clinical relevance of the various dissection proto-
cols and the interpretation of certain macroscopic and micro-
scopic parameters.
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